Related Experiment Video
Updated: Dec 20, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Impact of bleeding after transcatheter aortic valve replacement in patients with chronic kidney disease
Shawn X Li1, Nilay K Patel1, Laura D Flannery1
1Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Insights
Patients with chronic kidney disease (CKD) face increased bleeding risks after transcatheter aortic valve replacement (TAVR). This bleeding is linked to higher mortality, underscoring the need for careful management post-TAVR.
Area of Science:
- Cardiology
- Nephrology
- Transcatheter Aortic Valve Replacement (TAVR)
- Chronic Kidney Disease (CKD)
Background:
- Patients with chronic kidney disease (CKD) exhibit elevated bleeding risks post-transcatheter aortic valve replacement (TAVR).
- The persistence of bleeding risk beyond the immediate procedure and its impact on mortality in CKD patients undergoing TAVR remain unclear.
- Understanding these risks is crucial for optimizing patient care and outcomes.
Purpose of the Study:
- To investigate bleeding risks in patients with CKD undergoing TAVR.
- To determine the association between post-TAVR bleeding and subsequent mortality in CKD patients.
- To analyze antithrombotic therapy patterns in CKD patients post-TAVR.
Main Methods:
- Retrospective review of TAVR patients at Massachusetts General Hospital (2008-2017).
- CKD defined as estimated glomerular filtration rate < 60 mL/min/1.73 m².
- Primary endpoints included bleeding, all-cause mortality, and ischemic stroke up to 1 year post-TAVR, analyzed using Cox regression.
Main Results:
- 60.3% of analyzed patients had CKD. CKD patients showed higher 1-year bleeding rates (9.2% vs. 4.9%) and all-cause mortality (13.7% vs. 9.1%).
- Post-TAVR bleeding was significantly associated with increased subsequent mortality (aHR = 2.65, p = .01).
- No significant difference in stroke rates or antithrombotic strategies was observed between CKD and non-CKD groups.
Conclusions:
- Chronic kidney disease (CKD) is independently associated with increased bleeding risk up to one year following transcatheter aortic valve replacement (TAVR).
- Long-term bleeding events after TAVR in CKD patients are linked to a higher risk of subsequent mortality.
- Current antithrombotic strategies do not appear to differ between CKD and non-CKD patients post-TAVR.
Objective:
In patients with chronic kidney disease (CKD) undergoing transcatheter aortic valve replacement (TAVR), this study aims to elucidate (a) the bleeding risks associated with CKD, (b) the association between bleeding and subsequent mortality, and (c) the pattern of antithrombotic therapy prescribed.
Background:
Patients with CKD have a higher risk of bleeding following TAVR. It is unclear whether this risk persists beyond the periprocedural period and whether it negatively impacts mortality.
Methods:
A retrospective review was performed on patients who underwent TAVR at Massachusetts General Hospital from 2008 to 2017. CKD was defined as estimated glomerular filtration rate less than 60 ml/min/1.73 m2 . Primary endpoints up to 1-year following TAVR included bleeding, all-cause mortality, and ischemic stroke. Outcomes for patients with and without CKD were compared using log-rank test, and Cox regression with age, sex, and diabetes as covariates. Bleeding was treated as a time-varying covariate, and Cox proportional hazard regression was utilized to model mortality.
Results:
Of the 773 patients analyzed, 466 (60.3%) had CKD. At 1 year, CKD patients had higher rates of bleeding (9.2 vs. 4.9%, adjusted hazard ratios [aHR] = 1.91, p = .032) and all-cause mortality (13.7 vs. 9.1%, aHR = 1.57, p = .049), but not stroke (3.9 vs. 1.6% aHR = 0.073, p = .094). Bleeding was associated with an increased risk of subsequent mortality (aHR = 2.65, 95% CI: 1.25-5.63, p = .01). There were no differences in the antithrombotic strategy following TAVR between CKD and non-CKD patients.
Conclusion:
CKD is associated with a higher risk of bleeding up to 1 year following TAVR. Long-term bleeding after TAVR is associated with increased subsequent mortality.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Continuous Renal Replacement Therapy
Acute Kidney Injury I: Introduction
Chronic Kidney Disease II: Clinical Manifestations

